Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- Provectus Announces Preliminary Phase 2 Data For PH-10 In Its Psoriasis And Atopic Dermatitis Trials
- Gene Therapy Trial Succeeds In Spurring Production Of A Protective Protein
- New Data On Highly Effective Treatment For Chronic Rhinosinusitis With Nasal Polyps
- Cutting Breast Cancer Risk And Treating Symptoms Of Menopause With Hormone Mix
- FDA Warns of Fatal Overdose Risk with Propoxyphene
- Genzyme Phase 3 Trial Of Campath/Fludara Combination Shows Potential Benefit In Second-Line CLL
- Teach Your Patients About Their Medicines To Avoid Misadventure, UK
- New Report Finds Obesity Epidemic Increases, Mississippi Weighs In As Heaviest State
- Pharmaceutical Sector Inquiry - Highlights Regulatory Shortcomings And Need For A Strong, Effective Patent System In Europe
- FDA Approves Generic Emergency Contraceptive for Teens
IFPMA Announces Johnson & Johnson As New Member Company
Posted by: admin in Pharmacy Drugs on September 15th, 2009
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Johnson & Johnson has become its newest member company.
IFPMA Acting Director General Michael D. Boyd said: “Johnson & Johnson is an important company in our industry and one which is particularly active in working to help improve health in developing countries. The IFPMA is very pleased that Johnson & Johnson has joined; this is good for the IFPMA, and we expect it will benefit Johnson & Johnson, as well.”
Johnson & Johnson is the world’s most comprehensive healthcare company, with more than 250 companies in 57 countries employing 119,000 people worldwide engaged in the research and development, manufacture and sales of a broad range of health care products, including pharmaceuticals, medical devices and diagnostics. Its worldwide headquarters is in New Brunswick, New Jersey, USA.
The company is committed to bringing innovative ideas, products and services to market that advance the health and well-being of people throughout the world.
For general information on Johnson & Johnson, please go to http://www.jnj.com. For information on the company’s activities to help improve health in underserved communities, please go to http://www.jnj.com/connect/caring/medicine-access/.
Source
IFPMA
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.